» Articles » PMID: 29935655

Personalized Ovarian Stimulation for Assisted Reproductive Technology: Study Design Considerations to Move from Hype to Added Value for Patients

Overview
Journal Fertil Steril
Date 2018 Jun 25
PMID 29935655
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Although most medical treatments are designed for the average patient with a one-size-fits-all-approach, they may not benefit all. Better understanding of the function of genes, proteins, and metabolite, and of personal and environmental factors has led to a call for personalized medicine. Personalized reproductive medicine is still in its infancy, without clear guidance on treatment aspects that could be personalized and on trial design to evaluate personalized treatment effect and benefit-harm balance. While the rationale for a personalized approach often relies on retrospective analyses of large observational studies or real-world data, solid evidence of superiority of a personalized approach will come from randomized trials comparing outcomes and safety between a personalized and one-size-fits-all strategy. A more efficient, targeted randomized trial design may recruit only patients or couples for which the personalized approach would differ from the previous, standard approach. Multiple monocenter studies using the same study protocol (allowing future meta-analysis) might reduce the major center effect associated with multicenter studies. In certain cases, single-arm observational studies can generate the necessary evidence for a personalized approach. This review describes each of the main segments of patient care in assisted reproductive technologies treatment, addressing which aspects could be personalized, emphasizing current evidence and relevant study design.

Citing Articles

Assessing the uptake of infertility core outcome set in IVF randomized controlled trials.

Li W, Jia N, Chi H, Zhan S, Zeng L Hum Reprod. 2024; 40(1):85-95.

PMID: 39673431 PMC: 11700894. DOI: 10.1093/humrep/deae255.


From patient classification to optimized treatment in ART: the AMPLITUDE Delphi consensus.

Blockeel C, Guivarch-Leveque A, Rongieres C, Swierkowski-Blanchard N, Porcu-Buisson G, Yazbeck C Front Reprod Health. 2024; 6:1467322.

PMID: 39399814 PMC: 11466932. DOI: 10.3389/frph.2024.1467322.


Harnessing Artificial Intelligence to Predict Ovarian Stimulation Outcomes in In Vitro Fertilization: Scoping Review.

AlSaad R, Abd-Alrazaq A, Choucair F, Ahmed A, Aziz S, Sheikh J J Med Internet Res. 2024; 26:e53396.

PMID: 38967964 PMC: 11259766. DOI: 10.2196/53396.


Fine-tuning the dose of recombinant human follicle-stimulating hormone alfa to individualize treatment in ovulation induction and ovarian stimulation cycles: a real-world database analysis.

Martini A, Beall S, Ball G, Hayward B, DHooghe T, Mahony M Front Endocrinol (Lausanne). 2023; 14:1195632.

PMID: 37727455 PMC: 10505726. DOI: 10.3389/fendo.2023.1195632.


An Online Tool Using Basal or Activated Ovarian Reserve Markers to Predict the Number of Oocytes Retrieved Following Controlled Ovarian Stimulation: A Prospective Observational Cohort Study.

Han Y, Xu H, Feng G, Alpadi K, Chen L, Wang H Front Endocrinol (Lausanne). 2022; 13:881983.

PMID: 35692402 PMC: 9186016. DOI: 10.3389/fendo.2022.881983.